BeyondSpring Inc. (BYSI)
1.64
-0.04 (-2.38%)
At close: Mar 04, 2025, 11:38 AM
No 1D chart data available
| Bid | 1.61 |
| Market Cap | 66.05M |
| Revenue (ttm) | 1.94M |
| Net Income (ttm) | -16.06M |
| EPS (ttm) | -0.4 |
| PE Ratio (ttm) | -4.1 |
| Forward PE | -3.81 |
| Analyst | n/a |
| Ask | 1.68 |
| Volume | 17,662 |
| Avg. Volume (20D) | 19,165 |
| Open | 1.65 |
| Previous Close | 1.68 |
| Day's Range | 1.61 - 1.68 |
| 52-Week Range | 1.43 - 4.00 |
| Beta | 0.31 |
About BYSI
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combinati...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 9, 2017
Employees 36
Stock Exchange NASDAQ
Ticker Symbol BYSI
